S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic

Jazz Pharmaceuticals (JAZZ) Competitors

$118.85
-0.05 (-0.04%)
(As of 03/1/2024 ET)

JAZZ vs. PRGO, CORT, APLS, ELAN, VKTX, CYTK, ASND, CERE, ROIV, and ITCI

Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Perrigo (PRGO), Corcept Therapeutics (CORT), Apellis Pharmaceuticals (APLS), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Cytokinetics (CYTK), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Roivant Sciences (ROIV), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical preparations" industry.

Jazz Pharmaceuticals vs.

Perrigo (NYSE:PRGO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.

Jazz Pharmaceuticals received 326 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.37% of users gave Jazz Pharmaceuticals an outperform vote while only 66.75% of users gave Perrigo an outperform vote.

CompanyUnderperformOutperform
PerrigoOutperform Votes
759
66.75%
Underperform Votes
378
33.25%
Jazz PharmaceuticalsOutperform Votes
1085
80.37%
Underperform Votes
265
19.63%

Perrigo has higher revenue and earnings than Jazz Pharmaceuticals. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.66B0.77-$140.60M-$0.10-263.30
Jazz Pharmaceuticals$3.83B1.93-$224.06M$6.1219.42

Jazz Pharmaceuticals has a net margin of 10.82% compared to Jazz Pharmaceuticals' net margin of -0.27%. Perrigo's return on equity of 31.27% beat Jazz Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-0.27% 7.34% 3.24%
Jazz Pharmaceuticals 10.82%31.27%9.81%

In the previous week, Perrigo had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 41 mentions for Perrigo and 38 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.48 beat Perrigo's score of 0.27 indicating that Perrigo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
11 Very Positive mention(s)
2 Positive mention(s)
17 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Jazz Pharmaceuticals
9 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral

Perrigo presently has a consensus price target of $42.50, indicating a potential upside of 61.41%. Jazz Pharmaceuticals has a consensus price target of $190.70, indicating a potential upside of 60.45%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Perrigo is more favorable than Jazz Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Jazz Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82

Perrigo has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

95.7% of Perrigo shares are owned by institutional investors. Comparatively, 88.2% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.7% of Perrigo shares are owned by company insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Perrigo on 10 of the 18 factors compared between the two stocks.


Get Jazz Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JAZZ vs. The Competition

MetricJazz PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.41B$6.74B$5.11B$7.64B
Dividend YieldN/A2.83%2.82%3.87%
P/E Ratio19.429.89190.3415.69
Price / Sales1.93235.673,056.3377.06
Price / Cash4.2719.33100.6555.48
Price / Book1.984.654.534.53
Net Income-$224.06M$155.01M$115.01M$211.55M
7 Day Performance-10.15%7.79%5.72%3.36%
1 Month Performance-3.30%15.91%12.82%6.70%
1 Year Performance-18.66%8.07%12.94%7.44%

Jazz Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRGO
Perrigo
4.9837 of 5 stars
$27.30
-15.1%
$44.25
+62.1%
-31.2%$3.70B$4.65B546.118,900Earnings Report
Dividend Increase
Analyst Downgrade
Insider Buying
News Coverage
High Trading Volume
CORT
Corcept Therapeutics
4.7527 of 5 stars
$24.15
+4.4%
$33.79
+39.9%
+23.0%$2.50B$482.38M25.42299Positive News
APLS
Apellis Pharmaceuticals
4.0674 of 5 stars
$69.35
-3.3%
$75.93
+9.5%
-0.8%$8.22B$75.42M-13.21767Earnings Report
Analyst Report
Analyst Revision
News Coverage
ELAN
Elanco Animal Health
2.8817 of 5 stars
$16.47
+1.3%
$16.71
+1.5%
+45.6%$8.12B$4.37B-7.109,000Earnings Report
Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
Gap Up
VKTX
Viking Therapeutics
3.9796 of 5 stars
$85.05
+121.0%
$50.88
-40.2%
+643.0%$8.55BN/A-92.4427Analyst Report
Options Volume
Analyst Revision
News Coverage
Gap Up
High Trading Volume
CYTK
Cytokinetics
3.0456 of 5 stars
$80.99
+2.5%
$73.94
-8.7%
+86.8%$7.94B$94.59M-14.67409Earnings Report
Analyst Report
Analyst Revision
News Coverage
ASND
Ascendis Pharma A/S
1.0778 of 5 stars
$155.34
-1.4%
$158.29
+1.9%
+34.5%$8.96B$288.08M-16.79879
CERE
Cerevel Therapeutics
0.8 of 5 stars
$41.31
+0.6%
$39.64
-4.0%
+51.3%$7.49BN/A-16.52321Upcoming Earnings
Short Interest ↑
ROIV
Roivant Sciences
3.9683 of 5 stars
$11.80
+0.9%
$16.50
+39.8%
+45.3%$9.51B$61.28M2.27904Positive News
ITCI
Intra-Cellular Therapies
4.387 of 5 stars
$72.90
+1.9%
$81.42
+11.7%
+53.7%$7.06B$464.37M-49.93561Insider Selling
Short Interest ↓
Analyst Revision

Related Companies and Tools

This page (NASDAQ:JAZZ) was last updated on 3/3/2024 by MarketBeat.com Staff